Matches in Nanopublications for { ?s ?p "DDI between Abacavir and Valganciclovir - The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended. [drugbank_resource:DB01048_DB01610]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB01048_DB01610 label "DDI between Abacavir and Valganciclovir - The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended. [drugbank_resource:DB01048_DB01610]" assertion.